Biologic or Conventional Therapy for Early RA?
FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA
FDA Approves Risankizumab-rzaa for PsA
The Ins & Outs of Patient Assistance Programs
Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5
Defining Administration Complexity by the Drug, Not the Diagnosis
Therapeutics for COVID-19: An update from ACR Convergence 2021
The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis
FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved
- 1
- 2
- 3
- …
- 35
- Next Page »